Chief Business Officer Sarah Holland joins an expert panel at the LSX Informa Investival Showcase, sharing strategies for winning in today’s shifting biopharma and medtech partnering landscape.

Thrilled to expand our partnership w @boehringerglobal.bsky.social to advance CDR111, a trispecific M-gager® designed for broad B-cell depletion in autoimmune diseases. This validates the reach of our antibody fragment–based T-cell engager platform beyond oncology and retinal health. bit.ly/492ru2m

CDR-Life’s Sarah Holland joins #BIOEurope in Vienna to discuss our M-gager® platform, advancing potent, precise T cell engagers for solid tumors and autoimmune diseases.
Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!

Our team will be in London for #JefferiesHealthcare, sharing how our M-gager® platform is setting a new benchmark for T cell engager precision, unlocking new possibilities in both solid tumors and autoimmune diseases.

We welcome the chance to connect!

CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting!
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE

Meet Romina Doerig, Developability Expert at CDR-Life.
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.

Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!

CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer.

Built on our M-gager® platform. IND-enabling studies planned for H2 2025.

Details: bit.ly/46dO0ne

CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview:
pharmaboardroom.com/interviews/c...

We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf

Chicago bound! The CDR-Life team is heading to #ASCO25 to discuss our M-gager® platform and lead program CDR404, now in Phase 1 for MAGE-A4+ tumors as well as CDR609, our first program targeting a highly cancer specific surface antigen widely expressed in common tumor types. Let’s connect!!

Join CDR-Life at Swiss Biotech Day (May 5–6)! Hear from our VP Clare Price, and meet CEO Christian Leisner, and CBO Sarah Holland, as they showcase how M-gager® is transforming T cell engager therapy. Let’s connect! #SwissBiotechDay #immunotherapy